These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

757 related items for PubMed ID: 11450165

  • 1. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
    Schnack C, Schernthaner G.
    Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 4. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep 09; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 5. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
    Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, Yamamoto K, Kato T, Hayakawa N, Oda N, Goto Y, Goto Y, Nagasaka A, Senda T, Itoh M.
    Horm Metab Res; 2004 Jul 09; 36(7):458-64. PubMed ID: 15305228
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Jul 09; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

  • 7. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Jul 09; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 09; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 9. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar 09; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 10. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb 09; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 11. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A, Battegay E.
    Praxis (Bern 1994); 2005 Apr 13; 94(15):581-94. PubMed ID: 15884724
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec 13; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 13. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.
    Ugeskr Laeger; 2001 Oct 01; 163(40):5514-9. PubMed ID: 11601117
    [Abstract] [Full Text] [Related]

  • 14. [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
    Hauser AC, Hörl WH.
    Wien Med Wochenschr; 2001 Oct 01; 151(7-8):160-4. PubMed ID: 11450164
    [Abstract] [Full Text] [Related]

  • 15. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H, Yasuda G, Takizawa T, Shionoiri F.
    Nihon Rinsho; 2005 Jun 01; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract] [Full Text] [Related]

  • 16. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar 01; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

  • 17. [Are all antihypertensive drugs renoprotective?].
    Wolf S, Risler T.
    Herz; 2004 May 01; 29(3):248-54. PubMed ID: 15167950
    [Abstract] [Full Text] [Related]

  • 18. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul 01; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 19. Renal protection and antihypertensive drugs: current status.
    Salvetti A, Mattei P, Sudano I.
    Drugs; 1999 May 01; 57(5):665-93. PubMed ID: 10353294
    [Abstract] [Full Text] [Related]

  • 20. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep 01; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.